GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » Valuation Rank

Ceapro (TSXV:CZO) Valuation Rank


View and export this data going back to 1992. Start your Free Trial

What is Ceapro Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Ceapro Valuation Rank Related Terms

Thank you for viewing the detailed overview of Ceapro's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Ceapro (TSXV:CZO) Business Description

Traded in Other Exchanges
Address
7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2
Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.